CSF-1
Phase 2Small molecule
CSF-1 is one of 14 small molecule programs targeting Presbyopia. It is currently in Phase 2.
1
Indications
4
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Presbyopia
#DrugCompanyPhaseTrials
1Bromday
BBausch Health Americas, Inc.
Approved
Alphagan
AbbViePhase 3
Alphagan
NovartisPhase 3
Isopto Carpine
AAdvanz Pharma
Phase 3
Pilocarpine Hcl
AbbViePhase 3
Miostat
FFalcon
Phase 2
Restasis
TTaiwan Bio Therapeutics Inc.
Phase 1
AGN-199201
AbbViePhase 2
AGN-190584
AbbViePhase 2
BAY 2701439
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Presbyopia3 trials
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CSF-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- OOrasis Pharmaceuticals Ltd.